Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial

MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc.

MAIA

0.00
  • Maia Biotechnology opened enrollment at Emory University’s Winship Cancer Institute for its Phase 2 THIO-101 expansion trial in third-line NSCLC.
  • The study evaluates ateganosine, a telomere-targeting agent, followed by cemiplimab in patients resistant to checkpoint inhibitors and chemotherapy.
  • Early results from Parts A and B have already been presented, showing encouraging clinical benefit in some patients.
  • The U.S. expansion adds a third domestic site, supporting broader recruitment for a setting with no FDA-approved third-line options.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180830PRIMZONEFULLFEED9748867) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.